{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:56:00Z","timestamp":1790805360463,"version":"4.1.0"},"reference-count":249,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"DOI":"10.1038\/s41573-026-01535-y","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:33:29Z","timestamp":1790757209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Soft drugs: design principles and topical applications"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-4787","authenticated-orcid":false,"given":"Tracey","family":"Pirali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0046-7636","authenticated-orcid":false,"given":"Alessandro","family":"Accetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-3980","authenticated-orcid":false,"given":"Jarkko","family":"Rautio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-1526","authenticated-orcid":false,"given":"Laura","family":"Carzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1535_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X","volume":"20","author":"N Bodor","year":"2000","unstructured":"Bodor, N. & Buchwald, P. Soft drug design: general principles and recent applications. Med. Res. Rev. 20, 58\u2013101 (2000).This foundational review established the general principles, design criteria and early applications that defined soft drugs as a distinct retrometabolic drug design strategy.","journal-title":"Med. Res. Rev."},{"key":"1535_CR2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.31083\/ph.2014.3911R","volume":"69","author":"P Buchwald","year":"2014","unstructured":"Buchwald, P. & Bodor, N. Recent advances in the design and development of soft drugs. Pharmazie 69, 403\u2013413 (2014).","journal-title":"Pharmazie"},{"key":"1535_CR3","doi-asserted-by":"crossref","unstructured":"Bodor, N. & Buchwald, P. Soft Drugs in Retrometabolic Drug Design and Targeting (Wiley, 2012).","DOI":"10.1002\/9781118407738"},{"key":"1535_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrd.2018.46","volume":"17","author":"J Rautio","year":"2018","unstructured":"Rautio, J., Meanwell, N. A., Di, L. & Hageman, M. J. The expanding role of prodrugs in contemporary drug design and development. Nat. Rev. Drug Discov. 17, 559\u2013587 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1535_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41573-024-00914-7","volume":"23","author":"Z Fralish","year":"2024","unstructured":"Fralish, Z., Chen, A., Khan, S., Zhou, P. & Reker, D. The landscape of small-molecule prodrugs. Nat. Rev. Drug Discov. 23, 365\u2013380 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1535_CR6","doi-asserted-by":"crossref","unstructured":"Ari\u00ebns, E. J. Drug\u2013receptor interaction: interaction of one or more drugs with one receptor system. In Molecular Pharmacology (ed. Ari\u00ebns, E. J.) 119\u2013286 (Academic Press, 1964).","DOI":"10.1016\/B978-0-12-395640-8.50013-5"},{"key":"1535_CR7","doi-asserted-by":"publisher","first-page":"10233","DOI":"10.1021\/acs.jmedchem.2c00609","volume":"65","author":"L Carzaniga","year":"2022","unstructured":"Carzaniga, L. et al. Discovery of clinical candidate CHF-6366: a novel super-soft dual pharmacology muscarinic antagonist and \u03b22 agonist (MABA) for the inhaled treatment of respiratory diseases. J. Med. Chem. 65, 10233\u201310250 (2022).This study demonstrates the successful translation of a super-soft design into an inhaled clinical candidate combining dual pharmacology with rapid systemic deactivation.","journal-title":"J. Med. Chem."},{"key":"1535_CR8","doi-asserted-by":"publisher","first-page":"14502","DOI":"10.1021\/acs.jmedchem.0c00797","volume":"63","author":"J Larsen","year":"2020","unstructured":"Larsen, J. et al. Discovery and early clinical development of LEO 39652, a novel \u201cdual-soft\u201d PDE4 inhibitor for topical treatment of atopic dermatitis. J. Med. Chem. 63, 14502\u201314521 (2020).This work provides a comprehensive example of dual-soft design, using complementary blood and hepatic inactivation to minimize systemic exposure after topical administration.","journal-title":"J. Med. Chem."},{"key":"1535_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1021\/acsmedchemlett.8b00616","volume":"10","author":"M Bell","year":"2019","unstructured":"Bell, M. et al. Discovery of soft-drug topical tool modulators of sphingosine-1-phosphate receptor 1 (S1PR1). ACS Med. Chem. Lett. 10, 341\u2013347 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"1535_CR10","doi-asserted-by":"publisher","first-page":"6967","DOI":"10.1097\/MS9.0000000000004008","volume":"87","author":"HG Slam","year":"2025","unstructured":"Slam, H. G., Fatima, M., Sajid, H., Irshad, N. U. N. & Imran, S. B. FDA approval of aceclidine (Vizz): a new chapter in nonsurgical presbyopia management. Ann. Med. Surg. 87, 6967\u20136969 (2025).","journal-title":"Ann. Med. Surg."},{"key":"1535_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1021\/jm00179a001","volume":"23","author":"N Bodor","year":"1980","unstructured":"Bodor, N., Kaminski, J. J. & Selk, S. Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials. J. Med. Chem. 23, 469\u2013474 (1980).This seminal paper introduced the term soft drug and established metabolically labile active compounds as a rational drug design concept.","journal-title":"J. Med. Chem."},{"key":"1535_CR12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1021\/jm00179a018","volume":"23","author":"N Bodor","year":"1980","unstructured":"Bodor, N. & Kaminski, J. J. Soft drugs. 2. Soft alkylating compounds as potential antitumor agents. J. Med. Chem. 23, 566\u2013569 (1980).","journal-title":"J. Med. Chem."},{"key":"1535_CR13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/science.6296999","volume":"215","author":"HJ Lee","year":"1982","unstructured":"Lee, H. J. & Soliman, M. R. Anti-inflammatory steroids without pituitary\u2013adrenal suppression. Science 215, 989\u2013991 (1982).This landmark study established the antedrug concept by demonstrating potent local corticosteorid activity without systemic pituitary\u2013adrenal suppression.","journal-title":"Science"},{"key":"1535_CR14","doi-asserted-by":"publisher","first-page":"923353","DOI":"10.3389\/fphar.2022.923353","volume":"13","author":"C Deng","year":"2022","unstructured":"Deng, C., Liu, J. & Zhang, W. Structural modification in anesthetic drug development for prodrugs and soft drugs. Front. Pharmacol. 13, 923353 (2022).","journal-title":"Front. Pharmacol."},{"key":"1535_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/ALN.0b013e3181ae8460","volume":"111","author":"TD Egan","year":"2009","unstructured":"Egan, T. D. Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology 111, 229\u2013230 (2009).","journal-title":"Anesthesiology"},{"key":"1535_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/ACO.0000000000000879","volume":"33","author":"N Birgenheier","year":"2020","unstructured":"Birgenheier, N., Stuart, A. R. & Egan, T. D. Soft drugs in anesthesia: remifentanil as a prototype for modern anesthetic drug development. Curr. Opin. Anesthesiol. 33, 499\u2013505 (2020).","journal-title":"Curr. Opin. Anesthesiol."},{"key":"1535_CR17","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.bja.2018.01.038","volume":"120","author":"BI Valk","year":"2018","unstructured":"Valk, B. I. et al. Safety and clinical effect of i.v. infusion of cyclopropyl-methoxycarbonyl etomidate (ABP-700), a soft analogue of etomidate, in healthy subjects. Br. J. Anaesth. 120, 1401\u20131411 (2018).","journal-title":"Br. J. Anaesth."},{"key":"1535_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1213\/ANE.0000000000000804","volume":"121","author":"\u00c5 Norberg","year":"2015","unstructured":"Norberg, \u00c5 et al. First human study of the investigational sedative and anesthetic drug AZD3043: a dose-escalation trial to assess the safety, pharmacokinetics, and efficacy of a 30-minute infusion in healthy male volunteers. Anesth. Analg. 121, 885\u2013893 (2015).","journal-title":"Anesth. Analg."},{"key":"1535_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/cpdd.1383","volume":"13","author":"JE Ip","year":"2024","unstructured":"Ip, J. E. et al. Pharmacokinetics and pharmacodynamics of etripamil, an intranasally administered, fast-acting, nondihydropyridine calcium channel blocker. Clin. Pharmacol. Drug Dev. 13, 367\u2013379 (2024).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"1535_CR20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028227","volume":"12","author":"JE Ip","year":"2023","unstructured":"Ip, J. E. et al. Etripamil nasal spray for conversion of repeated spontaneous episodes of paroxysmal supraventricular tachycardia during long-term Follow-Up: results from the NODE-302 study. J. Am. Heart Assoc. 12, e028227 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"1535_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s40256-023-00589-2","volume":"23","author":"J Huston","year":"2023","unstructured":"Huston, J. et al. Etripamil nasal spray: therapeutic potential for treating paroxysmal supraventricular tachycardia. Am. J. Cardiovasc. Drugs 23, 471\u2013475 (2023).","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"1535_CR22","doi-asserted-by":"publisher","first-page":"12687","DOI":"10.1021\/acs.jmedchem.5c00538","volume":"68","author":"H Beck","year":"2025","unstructured":"Beck, H. et al. Discovery of BAY 3389934 hydrochloride: a potent and selective small-molecule dual factor IIa\/Xa inhibitor with short half-life for the acute treatment of sepsis-induced coagulopathy. J. Med. Chem. 68, 12687\u201312707 (2025).","journal-title":"J. Med. Chem."},{"key":"1535_CR23","first-page":"S5","volume":"21","author":"A Armstrong","year":"2022","unstructured":"Armstrong, A., Reddy, R., Chadha, D. & Kircik, L. A novel drug delivery method: retrometabolic drug design. J. Drugs Dermatol. 21, S5\u2013S10 (2022).","journal-title":"J. Drugs Dermatol."},{"key":"1535_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1385\/MB:26:2:123","volume":"26","author":"N Bodor","year":"2004","unstructured":"Bodor, N. & Buchwald, P. Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites. Mol. Biotechnol. 26, 123\u2013132 (2004).","journal-title":"Mol. Biotechnol."},{"key":"1535_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/17425255.2020.1777280","volume":"16","author":"P Buchwald","year":"2020","unstructured":"Buchwald, P. Soft drugs: design principles, success stories, and future perspectives. Expert Opin. Drug Metab. Toxicol. 16, 645\u2013650 (2020).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1535_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1515\/pac-2018-0208","volume":"93","author":"P Erhardt","year":"2021","unstructured":"Erhardt, P. et al. Glossary and tutorial of xenobiotic metabolism terms used during small molecule drug discovery and development (IUPAC Technical Report). Pure Appl. Chem. 93, 273\u2013403 (2021).","journal-title":"Pure Appl. Chem."},{"key":"1535_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cpdd.1561","volume":"14","author":"AFD Di Stefano","year":"2025","unstructured":"Di Stefano, A. F. D. et al. Pharmacokinetics, safety, and skin irritation and sensitization potential of clascoterone cream in early-phase clinical study participants. Clin. Pharmacol. Drug Dev. 14, 742\u2013753 (2025).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"1535_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1124\/dmd.112.048603","volume":"41","author":"AW Harrell","year":"2013","unstructured":"Harrell, A. W. et al. Metabolism and disposition of vilanterol, a long-acting \u03b22-adrenoceptor agonist for inhalation use in humans. Drug Metab. Dispos. 41, 89\u2013100 (2013).","journal-title":"Drug Metab. Dispos."},{"key":"1535_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1021\/acs.jmedchem.6b01634","volume":"60","author":"P Jones","year":"2017","unstructured":"Jones, P. et al. Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin. J. Med. Chem. 60, 767\u2013786 (2017).","journal-title":"J. Med. Chem."},{"key":"1535_CR30","doi-asserted-by":"publisher","first-page":"15391","DOI":"10.1021\/acs.jmedchem.6c00165","volume":"69","author":"S Subash","year":"2026","unstructured":"Subash, S. et al. Protein abundance of hydrolytic drug metabolizing enzymes in different tissues and across species. J. Med. Chem. 69, 15391\u201315402 (2026).","journal-title":"J. Med. Chem."},{"key":"1535_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1389557013407403","volume":"1","author":"P Buchwald","year":"2001","unstructured":"Buchwald, P. Structure\u2013metabolism relationships: steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev. Med. Chem. 1, 101\u2013111 (2001).","journal-title":"Mini Rev. Med. Chem."},{"key":"1535_CR32","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3390\/molecules23102615","volume":"23","author":"S Mahesh","year":"2018","unstructured":"Mahesh, S., Tang, K.-C. & Raj, M. Amide bond activation of biological molecules. Molecules 23, 2615 (2018).","journal-title":"Molecules"},{"key":"1535_CR33","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1124\/dmd.105.009043","volume":"34","author":"RE Pearce","year":"2006","unstructured":"Pearce, R. E. et al. Biotransformation of fluticasone: in vitro characterization. Drug Metab. Dispos. 34, 1035\u20131040 (2006).","journal-title":"Drug Metab. Dispos."},{"key":"1535_CR34","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1124\/dmd.108.022137","volume":"36","author":"SC Hughes","year":"2008","unstructured":"Hughes, S. C. et al. Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab. Dispos. 36, 2337\u20132344 (2008).","journal-title":"Drug Metab. Dispos."},{"key":"1535_CR35","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/phar.1598","volume":"35","author":"X Chen","year":"2015","unstructured":"Chen, X. et al. Pharmacodynamics and pharmacokinetics of fluticasone furoate\/vilanterol in healthy Chinese subject. Pharmacotherapy 35, 586\u2013599 (2015).","journal-title":"Pharmacotherapy"},{"key":"1535_CR36","first-page":"155","volume":"43","author":"L Thorsson","year":"2003","unstructured":"Thorsson, L. et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br. J. Pharmacol. 43, 155\u2013161 (2003).","journal-title":"Br. J. Pharmacol."},{"key":"1535_CR37","doi-asserted-by":"publisher","first-page":"23825","DOI":"10.1021\/acs.jmedchem.5c00830","volume":"68","author":"F Hulpia","year":"2025","unstructured":"Hulpia, F. et al. Discovery of gut-restricted PRMT5 inhibitors to intercept colorectal cancer in patients with genetic loss of tumor suppressor adenomatous polyposis coli. J. Med. Chem. 68, 23825\u201323866 (2025).This study demonstrates the deliberate use of aldehyde oxidase-mediated metabolism as a non-canonical soft spot to restrict pharmacological activity to the gastrointestinal tract.","journal-title":"J. Med. Chem."},{"key":"1535_CR38","doi-asserted-by":"publisher","first-page":"11865","DOI":"10.1074\/jbc.M112.449348","volume":"288","author":"F Daubeuf","year":"2013","unstructured":"Daubeuf, F. et al. An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in mice. J. Biol. Chem. 288, 11865\u201311876 (2013).","journal-title":"J. Biol. Chem."},{"key":"1535_CR39","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1093\/bja\/55.1.3","volume":"55","author":"JB Stenlake","year":"1983","unstructured":"Stenlake, J. B., Waigh, R. D., Urwin, J., Dewar, G. H. & Coker, G. G. Atracurium: conception and inception. Br. J. Anaesth. 55, 3S\u201310S (1983).","journal-title":"Br. J. Anaesth."},{"key":"1535_CR40","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1124\/dmd.109.031724","volume":"38","author":"J Albert\u00ed","year":"2010","unstructured":"Albert\u00ed, J., Martinet, A., Sentellas, S. & Salv\u00e0, M. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab. Dispos. 38, 1202\u20131210 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"1535_CR41","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.bmcl.2009.03.007","volume":"19","author":"T Akama","year":"2009","unstructured":"Akama, T. et al. Discovery and structure\u2013activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg. Med. Chem. Lett. 19, 2129\u20132132 (2009).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1535_CR42","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s00204-014-1218-6","volume":"88","author":"J Eilstein","year":"2014","unstructured":"Eilstein, J. et al. Comparison of xenobiotic-metabolizing enzyme activities in ex vivo human skin and reconstructed human skin models from SkinEthic. Arch. Toxicol. 88, 1681\u20131694 (2014).","journal-title":"Arch. Toxicol."},{"key":"1535_CR43","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000501732","volume":"32","author":"SM Pyo","year":"2019","unstructured":"Pyo, S. M. & Maibach, H. I. Skin metabolism: relevance of skin enzymes for rational drug design. Skin Pharmacol. Physiol. 32, 283\u2013293 (2019).","journal-title":"Skin Pharmacol. Physiol."},{"key":"1535_CR44","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.drudis.2019.08.007","volume":"24","author":"S Aprile","year":"2019","unstructured":"Aprile, S., Serafini, M. & Pirali, T. Soft drugs for dermatological applications: recent trends. Drug Discov. Today 24, 2234\u20132246 (2019).","journal-title":"Drug Discov. Today"},{"key":"1535_CR45","unstructured":"Bodor, N. S., Koleng, J. J. & Angulo, D. Formulation for soft anticholinergic analogs. US patent US20170020845 (2017)."},{"key":"1535_CR46","unstructured":"Bodor, N. S., Koleng, J. J. & Angulo, D. Formulation for soft anticholinergic analogs. Patent WO2017015485 (2017)."},{"key":"1535_CR47","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.xphs.2019.03.030","volume":"108","author":"A Samir","year":"2019","unstructured":"Samir, A., Ohura, K., Bodor, N. & Imai, T. Identification of the major esterase involved in the hydrolysis of a soft anticholinergic (2R,3\u2032R-SGM) designed from glycopyrrolate in human and rat tissues. J. Pharm. Sci. 108, 2791\u20132797 (2019).","journal-title":"J. Pharm. Sci."},{"key":"1535_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.33224\/rrch.2021.66.2.03","volume":"66","author":"N Bodor","year":"2021","unstructured":"Bodor, N. & Bodor, E. The first 40 years of soft anticholinergic agents. Rev. Roum. Chim. 66, 125\u2013133 (2021).","journal-title":"Rev. Roum. Chim."},{"key":"1535_CR49","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jaad.2020.02.016","volume":"82","author":"B Kirsch","year":"2020","unstructured":"Kirsch, B. Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: a phase II, randomized, controlled, double-blind trial. J. Am. Acad. Dermatol. 82, 1321\u20131327 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1535_CR50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/1346-8138.15927","volume":"48","author":"T Fujimoto","year":"2021","unstructured":"Fujimoto, T. et al. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J. Dermatol. 48, 1149\u20131161 (2021).","journal-title":"J. Dermatol."},{"key":"1535_CR51","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/1346-8138.15668","volume":"48","author":"H Yokozeki","year":"2021","unstructured":"Yokozeki, H. et al. A phase III, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J. Dermatol. 48, 279\u2013288 (2021).","journal-title":"J. Dermatol."},{"key":"1535_CR52","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s40265-020-01438-1","volume":"80","author":"J Paik","year":"2020","unstructured":"Paik, J. Sofpironium bromide: first approval. Drugs 80, 1981\u20131986 (2020).","journal-title":"Drugs"},{"key":"1535_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/13543784.2022.2017880","volume":"31","author":"S Gregoriou","year":"2022","unstructured":"Gregoriou, S., Tsiogka, A., Kontochristopoulos, G., Offidani, A. & Campanati, A. Sofpironium bromide: an investigational agent for axillary hyperhidrosis. Expert Opin. Investig. Drugs 31, 15\u201321 (2022).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1535_CR54","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/JD9.0000000000000417","volume":"8","author":"H Kuwahara","year":"2025","unstructured":"Kuwahara, H., Kubomura, K., Tsurugaya, Y. & Akaishi, S. Clinical efficacy of sofpironium bromide in reducing odor intensity in axillary osmidrosis complicated by primary axillary hyperhidrosis: a cohort study. Int. J. Dermatol. Venereol. 8, 72\u201376 (2025).","journal-title":"Int. J. Dermatol. Venereol."},{"key":"1535_CR55","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1007\/s00105-013-2597-y","volume":"64","author":"CM Salavastru","year":"2013","unstructured":"Salavastru, C. M., Fritz, K. & Tiplica, G. S. Spironolacton in dermatologischen Behandlungen. \u2018On-label-\u2019 und Off-label-Indikationen [Spironolactone in dermatological treatment. On and off label indications]. Hautarzt 64, 762\u2013767 (2013).","journal-title":"Hautarzt"},{"key":"1535_CR56","first-page":"563","volume":"18","author":"A Mazzetti","year":"2019","unstructured":"Mazzetti, A., Moro, L., Gerloni, M. & Cartwright, M. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17\u03b1-propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase IIa study. J. Drugs Dermatol. 18, 563 (2019).","journal-title":"J. Drugs Dermatol."},{"key":"1535_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2133.2011.10332.x","volume":"165","author":"V Trifu","year":"2011","unstructured":"Trifu, V. et al. Cortexolone 17\u03b1-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris: a pilot randomized, double-blind comparative study versus placebo and tretinoin 0.05% cream. Br. J. Dermatol. 165, 177\u2013183 (2011).","journal-title":"Br. J. Dermatol."},{"key":"1535_CR58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","volume":"156","author":"A Hebert","year":"2020","unstructured":"Hebert, A. et al. Efficacy and safety of topical clascoterone cream, 1%, for facial acne. JAMA Dermatol. 156, 621\u2013630 (2020).","journal-title":"JAMA Dermatol."},{"key":"1535_CR59","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jaad.2020.04.087","volume":"83","author":"L Eichenfield","year":"2020","unstructured":"Eichenfield, L. et al. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. J. Am. Acad. Dermatol. 83, 477\u2013485 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1535_CR60","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2147\/CCID.S289750","volume":"15","author":"C Sanchez","year":"2022","unstructured":"Sanchez, C. & Keri, J. Androgen receptor inhibitors in the treatment of acne vulgaris: efficacy and safety profiles of clascoterone 1% cream. Clin. Cosmet. Investig. Dermatol. 15, 1357\u20131366 (2022).","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"1535_CR61","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s40265-020-01417-6","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Clascoterone: first approval. Drugs 80, 1745\u20131750 (2020).","journal-title":"Drugs"},{"key":"1535_CR62","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.clinthera.2021.08.007","volume":"43","author":"CR Piszczatoski","year":"2021","unstructured":"Piszczatoski, C. R. & Powell, J. Topical clascoterone: the first novel agent for acne vulgaris in 40 years. Clin. Ther. 43, 1638\u20131644 (2021).","journal-title":"Clin. Ther."},{"key":"1535_CR63","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1177\/1060028021992053","volume":"55","author":"J Kalabalik-Hoganson","year":"2021","unstructured":"Kalabalik-Hoganson, J., Frey, K. M., Ozdener-Poyraz, A. E. & Slugocki, M. Clascoterone: a novel topical androgen receptor inhibitor for acne. Ann. Pharmacother. 55, 1290\u20131296 (2021).","journal-title":"Ann. Pharmacother."},{"key":"1535_CR64","doi-asserted-by":"publisher","first-page":"73361s3","DOI":"10.36849\/JDD.73361","volume":"24","author":"C Lynde","year":"2025","unstructured":"Lynde, C. et al. Real-world cases of clascoterone topical treatment for acne and related disorders. J. Drugs Dermatol. 24, 73361s3\u201373361s14 (2025).","journal-title":"J. Drugs Dermatol."},{"key":"1535_CR65","doi-asserted-by":"publisher","first-page":"16428","DOI":"10.1021\/acs.jmedchem.5c03640","volume":"69","author":"Y Zhang","year":"2026","unstructured":"Zhang, Y. et al. Novel dual soft drug strategy enables development of topical androgen receptor antagonists with enhanced efficacy and optimized safety for androgenetic alopecia. J. Med. Chem. 69, 16428\u201316454 (2026).This study illustrates a contemporary dual-soft strategy in which complementary liabilities improve skin retention while minimizing systemic exposure.","journal-title":"J. Med. Chem."},{"key":"1535_CR66","doi-asserted-by":"publisher","first-page":"631","DOI":"10.36849\/JDD.9089","volume":"24","author":"NT Issa","year":"2025","unstructured":"Issa, N. T. et al. PDE4 inhibitors: bridging molecular insights with clinical impact. J. Drugs Dermatol. 24, 631\u2013633 (2025).","journal-title":"J. Drugs Dermatol."},{"key":"1535_CR67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1124\/jpet.123.001609","volume":"386","author":"H Hiyama","year":"2023","unstructured":"Hiyama, H. et al. Pharmacological profile of difamilast, a novel selective phosphodiesterase 4 inhibitor, for topical treatment of atopic dermatitis. J. Pharmacol. Exp. Ther. 386, 45\u201355 (2023).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1535_CR68","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/8755122519844507","volume":"35","author":"L McDowell","year":"2019","unstructured":"McDowell, L. & Olin, B. Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis. J. Pharm. Technol. 35, 172\u2013178 (2019).","journal-title":"J. Pharm. Technol."},{"key":"1535_CR69","doi-asserted-by":"publisher","first-page":"116748","DOI":"10.1016\/j.bmc.2022.116748","volume":"63","author":"BC Das","year":"2022","unstructured":"Das, B. C. et al. Boron-containing heterocycles as promising pharmacological agents. Bioorg. Med. Chem. 63, 116748 (2022).","journal-title":"Bioorg. Med. Chem."},{"key":"1535_CR70","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/pde.12780","volume":"33","author":"WL Tom","year":"2016","unstructured":"Tom, W. L., Van Syoc, M., Chanda, S. & Zane, L. T. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study. Pediatr. Dermatol. 33, 150\u2013159 (2016).","journal-title":"Pediatr. Dermatol."},{"key":"1535_CR71","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","volume":"21","author":"J Schlessinger","year":"2020","unstructured":"Schlessinger, J. et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study. Am. J. Clin. Dermatol. 21, 275\u2013284 (2020).","journal-title":"Am. J. Clin. Dermatol."},{"key":"1535_CR72","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2217\/imt-2016-0023","volume":"8","author":"LT Zane","year":"2016","unstructured":"Zane, L. T. et al. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy 8, 853\u2013866 (2016).","journal-title":"Immunotherapy"},{"key":"1535_CR73","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaad.2019.06.1288","volume":"82","author":"PW Hashim","year":"2020","unstructured":"Hashim, P. W. et al. Crisaborole 2% ointment for intertriginous, anogenital, and facial psoriasis. J. Am. Acad. Dermatol. 82, 360\u2013365 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1535_CR74","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jamadermatol.2023.4990","volume":"160","author":"LF Eichenfield","year":"2024","unstructured":"Eichenfield, L. F. et al. Efficacy and safety of PF-07038124 in patients with atopic dermatitis and plaque psoriasis: a randomized clinical trial. JAMA Dermatol. 160, 156\u2013163 (2024).","journal-title":"JAMA Dermatol."},{"key":"1535_CR75","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00408-004-2518-z","volume":"182","author":"KM Beeh","year":"2004","unstructured":"Beeh, K. M. Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung 182, 369\u2013377 (2004).","journal-title":"Lung"},{"key":"1535_CR76","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1021\/jm500378a","volume":"57","author":"J Felding","year":"2014","unstructured":"Felding, J. et al. Discovery and early clinical development of LEO 29102, a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis. J. Med. Chem. 57, 5893\u20135903 (2014).","journal-title":"J. Med. Chem."},{"key":"1535_CR77","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11095-020-02962-1","volume":"37","author":"S Eirefelt","year":"2020","unstructured":"Eirefelt, S. et al. Evaluating dermal pharmacokinetics and pharmacodynamic effects of soft topical PDE4 inhibitors using open-flow microperfusion and skin biopsies. Pharm. Res. 37, 243 (2020).This study demonstrates how direct measurement of dermal pharmacokinetics can identify the exposure limitations that determine the clinical success or failure of topical soft drugs.","journal-title":"Pharm. Res."},{"key":"1535_CR78","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/exd.12377","volume":"23","author":"T Andoh","year":"2014","unstructured":"Andoh, T., Yoshida, T. & Kuraishi, Y. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp. Dermatol. 23, 359\u2013361 (2014).","journal-title":"Exp. Dermatol."},{"key":"1535_CR79","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/1346-8138.12534","volume":"41","author":"M Furue","year":"2014","unstructured":"Furue, M. et al. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis. J. Dermatol. 41, 577\u2013585 (2014).","journal-title":"J. Dermatol."},{"key":"1535_CR80","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/09546634.2016.1157257","volume":"27","author":"F Ohba","year":"2016","unstructured":"Ohba, F. et al. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis. J. Dermatolog. Treat. 27, 467\u2013472 (2016).","journal-title":"J. Dermatolog. Treat."},{"key":"1535_CR81","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/1346-8138.13231","volume":"43","author":"O Nemoto","year":"2016","unstructured":"Nemoto, O. et al. Effect of topical phosphodiesterase 4 inhibitor E6005 in Japanese children with atopic dermatitis. J. Dermatol. 43, 881\u2013887 (2016).","journal-title":"J. Dermatol."},{"key":"1535_CR82","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejphar.2015.10.013","volume":"768","author":"S Kubota","year":"2015","unstructured":"Kubota, S. et al. An inhaled phosphodiesterase-4 inhibitor, E6005, suppresses pulmonary inflammation in mice. Eur. J. Pharmacol. 768, 41\u201348 (2015).","journal-title":"Eur. J. Pharmacol."},{"key":"1535_CR83","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1124\/jpet.113.205542","volume":"346","author":"N Ishii","year":"2013","unstructured":"Ishii, N. et al. Antipruritic effects of the topical phosphodiesterase-4 inhibitor E6005 in a mouse model of atopic dermatitis. J. Pharmacol. Exp. Ther. 346, 105\u2013112 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1535_CR84","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1021\/cr068203e","volume":"108","author":"MOF Khan","year":"2008","unstructured":"Khan, M. O. F. & Lee, H. J. Synthesis and pharmacology of anti-inflammatory steroidal antedrugs. Chem. Rev. 108, 5131\u20135145 (2008).","journal-title":"Chem. Rev."},{"key":"1535_CR85","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.drudis.2021.09.005","volume":"27","author":"E Pasqua","year":"2022","unstructured":"Pasqua, E., Hamblin, N., Edwards, C., Baker-Glenn, C. & Hurley, C. Developing inhaled drugs for respiratory diseases: a medicinal chemistry perspective. Drug Discov. Today 27, 134\u2013150 (2022).","journal-title":"Drug Discov. Today"},{"key":"1535_CR86","first-page":"501","volume":"9","author":"P Hogger","year":"1998","unstructured":"Hogger, P. & Rohdewald, P. Glucocorticoid receptors and fluticasone propionate. Rev. Contemp. Pharmacother. 9, 501\u2013522 (1998).","journal-title":"Rev. Contemp. Pharmacother."},{"key":"1535_CR87","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/ardp.201400165","volume":"347","author":"V Dobri\u010di\u0107","year":"2014","unstructured":"Dobri\u010di\u0107, V. et al. Design, synthesis and local anti-inflammatory activity of 17\u03b2-carboxamide derivatives of glucocorticoids. Arch. Pharm. Chem. Life Sci. 347, 786\u2013797 (2014).","journal-title":"Arch. Pharm. Chem. Life Sci."},{"key":"1535_CR88","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejps.2013.10.017","volume":"52","author":"V Dobri\u010di\u0107","year":"2014","unstructured":"Dobri\u010di\u0107, V., Nikoli\u0107, K., Vladimirov, S. & \u010cudina, O. Quantitative structure\u2013activity relationships of glucocorticoid soft drugs. Eur. J. Pharm. Sci. 52, 95\u2013108 (2014).","journal-title":"Eur. J. Pharm. Sci."},{"key":"1535_CR89","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/jphp.12819","volume":"69","author":"N Bodor","year":"2017","unstructured":"Bodor, N., Zubovics, Z., Kurucz, I., S\u00f3lyom, S. & Bodor, E. Potent analogues of etiprednol dicloacetate: a second generation of soft corticosteroids. J. Pharm. Pharmacol. 69, 1745\u20131753 (2017).","journal-title":"J. Pharm. Pharmacol."},{"key":"1535_CR90","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.steroids.2005.08.005","volume":"71","author":"KK Park","year":"2006","unstructured":"Park, K. K., Ko, D. H., You, Z., Heiman, A. S. & Lee, H. J. 9\u03b1-Fluoro-11\u03b2,17\u03b1,21-trihydroxy-3,20-dioxo-pregna-1,4-diene-16\u03b1-carboxylate (FP16CM) and its derivatives. Steroids 71, 83\u201389 (2006).","journal-title":"Steroids"},{"key":"1535_CR91","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1124\/jpet.103.053652","volume":"307","author":"I Kurucz","year":"2003","unstructured":"Kurucz, I. et al. Potency and specificity of the pharmacological action of etiprednol dicloacetate (BNP-166), a novel antiasthmatic soft steroid for topical administration. J. Pharmacol. Exp. Ther. 307, 83\u201392 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1535_CR92","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1021\/jm990436t","volume":"43","author":"K Biggadike","year":"2000","unstructured":"Biggadike, K. et al. Selective plasma hydrolysis of glucocorticoid \u03b3-lactones and cyclic carbonates by paraoxonase: an ideal plasma inactivation mechanism. J. Med. Chem. 43, 19\u201321 (2000).This paper established selective plasma hydrolysis by paraoxonase as an effective mechanism for preserving local activity while enabling rapid systemic inactivation.","journal-title":"J. Med. Chem."},{"key":"1535_CR93","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/jm001035c","volume":"44","author":"PA Procopiou","year":"2001","unstructured":"Procopiou, P. A. et al. Novel glucocorticoid antedrugs possessing a 17\u03b2-(\u03b3-lactone) ring. J. Med. Chem. 44, 602\u2013612 (2001).","journal-title":"J. Med. Chem."},{"key":"1535_CR94","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1039\/b200190j","volume":"1","author":"RM Angell","year":"2002","unstructured":"Angell, R. M. et al. Novel glucocorticoid antedrugs possessing a 21-(\u03b3-lactone) ring. J. Chem. Soc., Perkin Trans. 1, 831\u2013839 (2002).","journal-title":"J. Chem. Soc., Perkin Trans."},{"key":"1535_CR95","doi-asserted-by":"publisher","first-page":"8591","DOI":"10.1021\/acs.jmedchem.7b01215","volume":"60","author":"M Hemmerling","year":"2017","unstructured":"Hemmerling, M. et al. Selective nonsteroidal glucocorticoid receptor modulators for the inhaled treatment of pulmonary diseases. J. Med. Chem. 60, 8591\u20138605 (2017).","journal-title":"J. Med. Chem."},{"key":"1535_CR96","doi-asserted-by":"publisher","first-page":"127402","DOI":"10.1016\/j.bmcl.2020.127402","volume":"30","author":"KN Dack","year":"2020","unstructured":"Dack, K. N. et al. Topical \u2018dual-soft\u2019 glucocorticoid receptor agonists for dermatology. Bioorg. Med. Chem. Lett. 30, 127402 (2020).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1535_CR97","unstructured":"Johnson, P. S., Dack, K. N. & Henriksson, K. Non-steroidal glucocorticoid receptor modulators for local drug delivery. Patent WO2017046096 (2017)."},{"key":"1535_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05471-w","volume":"12","author":"S Eirefelt","year":"2022","unstructured":"Eirefelt, S. et al. Characterization of a novel nonsteroidal glucocorticoid receptor agonist optimized for topical treatment. Sci. Rep. 12, 1501 (2022).","journal-title":"Sci. Rep."},{"key":"1535_CR99","doi-asserted-by":"publisher","first-page":"930964","DOI":"10.3389\/fnmol.2022.930964","volume":"15","author":"A Fern\u00e1ndez-Carvajal","year":"2022","unstructured":"Fern\u00e1ndez-Carvajal, A., Fern\u00e1ndez-Ballester, G. & Ferrer-Montiel, A. TRPV1 in chronic pruritus and pain: soft modulation as a therapeutic strategy. Front. Mol. Neurosci. 15, 930964 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"1535_CR100","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1021\/jm070190p","volume":"50","author":"EM Doherty","year":"2007","unstructured":"Doherty, E. M. et al. Novel vanilloid receptor-1 antagonists: structure\u2013activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. J. Med. Chem. 50, 3515\u20133527 (2007).","journal-title":"J. Med. Chem."},{"key":"1535_CR101","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/B978-0-12-396493-9.00002-9","volume":"51","author":"ME Kort","year":"2012","unstructured":"Kort, M. E. & Kym, P. R. TRPV1 antagonists: clinical setbacks and prospects for future development. Prog. Med. Chem. 51, 57\u201370 (2012).","journal-title":"Prog. Med. Chem."},{"key":"1535_CR102","unstructured":"Banerjee, S. & McCormack, S. Capsaicin for Acute or Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness (Canadian Agency for Drugs and Technologies in Health, 2020)."},{"key":"1535_CR103","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/a-2309-5581","volume":"74","author":"GK Radhakrishna","year":"2024","unstructured":"Radhakrishna, G. K. et al. A comprehensive review of capsaicin and its role in cancer prevention and treatment. Drug Res. 74, 195\u2013207 (2024).","journal-title":"Drug Res."},{"key":"1535_CR104","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jaci.2021.09.024","volume":"149","author":"CW Park","year":"2022","unstructured":"Park, C. W. et al. Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: phase III randomized, vehicle-controlled study (CAPTAIN-AD). J. Allergy Clin. Immunol. 149, 1340\u2013134.e4 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1535_CR105","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-1-4939-9446-5_13","volume":"1987","author":"T Pirali","year":"2019","unstructured":"Pirali, T. et al. Drug discovery for soft drugs on TRPV1 and TRPM8 channels using the Passerini reaction. Methods Mol. Biol. 1987, 207\u2013221 (2019).","journal-title":"Methods Mol. Biol."},{"key":"1535_CR106","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1021\/acs.jmedchem.8b00109","volume":"61","author":"M Serafini","year":"2018","unstructured":"Serafini, M. et al. Targeting transient receptor potential vanilloid 1 (TRPV1) channel softly: discovery of Passerini adducts as a topical treatment for inflammatory skin disorders. J. Med. Chem. 61, 4436\u20134455 (2018).This study demonstrates how incorporation of an estarase-labile soft spot can transform problematic systemic TRPV1 pharmacology into a locally acting topical strategy.","journal-title":"J. Med. Chem."},{"key":"1535_CR107","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1021\/acsmedchemlett.8b00618","volume":"10","author":"RB Kargbo","year":"2019","unstructured":"Kargbo, R. B. TRPV1 modulators for treatment of pain and inflammation. ACS Med. Chem. Lett. 10, 143\u2013144 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"1535_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-80725-z","volume":"11","author":"M Nikolaeva-Koleva","year":"2021","unstructured":"Nikolaeva-Koleva, M. et al. A capsaicinoid-based soft drug, AG1529, for attenuating TRPV1-mediated histaminergic and inflammatory sensory neuron excitability. Sci. Rep. 11, 246 (2021).","journal-title":"Sci. Rep."},{"key":"1535_CR109","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s12094-025-04062-1","volume":"28","author":"S Servitjia","year":"2025","unstructured":"Servitjia, S. et al. A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study. Clin. Transl. Oncol. 28, 1040\u20131048 (2025).","journal-title":"Clin. Transl. Oncol."},{"key":"1535_CR110","doi-asserted-by":"publisher","first-page":"116845","DOI":"10.1016\/j.ejmech.2024.116845","volume":"279","author":"A Lamberti","year":"2024","unstructured":"Lamberti, A. et al. The multicomponent Passerini reaction as a means of accessing diversity in structure, activity and properties: soft and hard vanilloid\/cannabinoid modulators. Eur. J. Med. Chem. 279, 116845 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1535_CR111","doi-asserted-by":"publisher","first-page":"s16","DOI":"10.36849\/JDD.49143","volume":"24","author":"NT Issa","year":"2025","unstructured":"Issa, N. T., Kwong, P., Bunick, C. G. & Kircik, L. Ruxolitinib 1.5% cream and the \u2018Boxed Warning Paradox\u2019: reappraisal of safety through the lens of pharmacokinetics. J. Drugs Dermatol. 24, s16\u2013s22 (2025).","journal-title":"J. Drugs Dermatol."},{"key":"1535_CR112","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1021\/acs.jmedchem.2c01977","volume":"66","author":"G Thoma","year":"2023","unstructured":"Thoma, G. et al. Discovery and characterization of the topical soft JAK inhibitor CEE321 for atopic dermatitis. J. Med. Chem. 66, 2161\u20132168 (2023).","journal-title":"J. Med. Chem."},{"key":"1535_CR113","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1021\/acsmedchemlett.3c00169","volume":"14","author":"G Thoma","year":"2023","unstructured":"Thoma, G. et al. Novel concept for super-soft topical drugs: deactivation by an enzyme-induced switch into an inactive conformation. ACS Med. Chem. Lett. 14, 841\u2013845 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"1535_CR114","doi-asserted-by":"publisher","first-page":"15042","DOI":"10.1021\/acs.jmedchem.3c01735","volume":"66","author":"G Thoma","year":"2023","unstructured":"Thoma, G. et al. Design of a supersoft topical JAK inhibitor effective in human skin but rapidly deactivated in blood. J. Med. Chem. 66, 15042\u201315053 (2023).This work validates a super-soft topical JAK inhibitor that retains activity in human skin while being rapidly converted into an inactive, poorly permeable metabolite.","journal-title":"J. Med. Chem."},{"key":"1535_CR115","doi-asserted-by":"publisher","first-page":"100251","DOI":"10.1016\/j.xjidi.2023.100251","volume":"4","author":"P Changelian","year":"2023","unstructured":"Changelian, P. et al. ATI-1777, a topical JAK1\/3 inhibitor, may benefit atopic dermatitis without systemic drug exposure: results from preclinical development and a phase 2a randomized controlled study. JID Innov. 4, 100251 (2023).","journal-title":"JID Innov."},{"key":"1535_CR116","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/acsmedchemlett.6b00087","volume":"7","author":"A Ritz\u00e9n","year":"2016","unstructured":"Ritz\u00e9n, A. et al. Fragment-based discovery of 6-arylindazole JAK inhibitors. ACS Med. Chem. Lett. 7, 641\u2013646 (2016).","journal-title":"ACS Med. Chem. Lett."},{"key":"1535_CR117","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02213861 (2016)."},{"key":"1535_CR118","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-21-0560","volume":"27","author":"JM Kilgour","year":"2021","unstructured":"Kilgour, J. M. et al. Phase II open-label, single-arm trial to investigate the efficacy and safety of topical remetinostat gel in patients with basal cell carcinoma. Clin. Cancer Res. 27, 4717\u20134725 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1535_CR119","doi-asserted-by":"publisher","first-page":"177011","DOI":"10.1016\/j.ejphar.2024.177011","volume":"983","author":"L Jin","year":"2024","unstructured":"Jin, L., Jiang, Q., Huang, H. & Zhou, X. Topical histone deacetylase inhibitor remetinostat improves imiquimod-induced psoriatic dermatitis by suppressing dendritic cell maturation and keratinocyte differentiation and inflammation. Eur. J. Pharmacol. 983, 177011 (2024).","journal-title":"Eur. J. Pharmacol."},{"key":"1535_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202400450","volume":"357","author":"J Seitz","year":"2024","unstructured":"Seitz, J. et al. Soft-drug inhibitors for the epigenetic targets lysine-specific demethylase 1 and histone deacetylases. Arch. Pharm. 357, e2400450 (2024).","journal-title":"Arch. Pharm."},{"key":"1535_CR121","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","volume":"81","author":"T P\u00e9rez-Jeldres","year":"2021","unstructured":"P\u00e9rez-Jeldres, T., \u00c1lvarez-Lobos, M. & Rivera-Nieves, J. Targeting sphingosine-1-phosphate signalling in immune-mediated diseases: beyond multiple sclerosis. Drugs 81, 985\u20131002 (2021).","journal-title":"Drugs"},{"key":"1535_CR122","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","volume":"384","author":"A Vaclavkova","year":"2014","unstructured":"Vaclavkova, A. et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase II trial. Lancet 384, 2036\u20132045 (2014).","journal-title":"Lancet"},{"key":"1535_CR123","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1016\/j.bmcl.2018.07.044","volume":"28","author":"M Bell","year":"2018","unstructured":"Bell, M. et al. Discovery of super-soft drug modulators of sphingosine-1-phosphate receptor 1. Bioorg. Med. Chem. Lett. 28, 3255\u20133259 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1535_CR124","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/17425255.2021.1908262","volume":"17","author":"Z Enlo-Scott","year":"2021","unstructured":"Enlo-Scott, Z., B\u00e4ckstr\u00f6m, E., Mudway, I. S. & Forbes, B. Drug metabolism in the lungs: opportunities for optimising inhaled medicines. Expert Opin. Drug Metab. Toxicol. 17, 611\u2013625 (2021).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1535_CR125","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1752-699X.2011.00244.x","volume":"5","author":"K Biggadike","year":"2011","unstructured":"Biggadike, K. Fluticasone furoate\/fluticasone propionate \u2014 different drugs with different properties. Clin. Respir. J. 5, 183 (2011).","journal-title":"Clin. Respir. J."},{"key":"1535_CR126","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1021\/jm800279t","volume":"51","author":"K Biggadike","year":"2008","unstructured":"Biggadike, K. et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor ligand-binding domain. J. Med. Chem. 51, 3349\u20133352 (2008).","journal-title":"J. Med. Chem."},{"key":"1535_CR127","doi-asserted-by":"publisher","first-page":"L660","DOI":"10.1152\/ajplung.00108.2007","volume":"293","author":"M Salter","year":"2007","unstructured":"Salter, M. et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am. J. Physiol. Lung Cell Mol. Physiol. 293, L660\u2013L667 (2007).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1535_CR128","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.2147\/JAA.S321332","volume":"14","author":"PT Daley-Yates","year":"2021","unstructured":"Daley-Yates, P. T., Larenas-Linnemann, D., Bhargave, C. & Verma, M. Intranasal corticosteroids: topical potency, systemic activity and therapeutic index. J. Asthma Allergy 14, 1093\u20131104 (2021).","journal-title":"J. Asthma Allergy"},{"key":"1535_CR129","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1021\/jm900132z","volume":"52","author":"M Prat","year":"2009","unstructured":"Prat, M. et al. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J. Med. Chem. 52, 5076\u20135092 (2009).This study demonstrates how receptor potency, prolonged pulmonary action and rapid systemic ester hydrolysis were integrated in the successful design of aclidinium.","journal-title":"J. Med. Chem."},{"key":"1535_CR130","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40265-018-1036-x","volume":"79","author":"YA Heo","year":"2019","unstructured":"Heo, Y. A. Revefenacin: first global approval. Drugs 79, 85\u201391 (2019).","journal-title":"Drugs"},{"key":"1535_CR131","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12931-017-0647-1","volume":"18","author":"KK Pudi","year":"2017","unstructured":"Pudi, K. K., Barnes, C. N., Moran, E. J., Haumann, B. & Kerwin, E. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease. Respir. Res. 18, 182 (2017).","journal-title":"Respir. Res."},{"key":"1535_CR132","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1124\/dmd.120.000103","volume":"48","author":"DL Bourdet","year":"2020","unstructured":"Bourdet, D. L. et al. Revefenacin absorption, metabolism, and excretion in healthy subjects and pharmacological activity of its major metabolite. Drug Metab. Dispos. 48, 1312\u20131320 (2020).","journal-title":"Drug Metab. Dispos."},{"key":"1535_CR133","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1021\/jm100326d","volume":"53","author":"PA Procopiou","year":"2010","unstructured":"Procopiou, P. A. et al. Long-acting \u03b22 agonists incorporating metabolic inactivation: an antedrug approach. J. Med. Chem. 53, 4522\u20134530 (2010).","journal-title":"J. Med. Chem."},{"key":"1535_CR134","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/00498254.2023.2230490","volume":"53","author":"A Ghiglieri","year":"2023","unstructured":"Ghiglieri, A. et al. ADME properties of CHF-6366, a novel bifunctional M3 muscarinic receptor antagonist and \u03b22 adrenoceptor agonist (MABA) radiolabelled at both functional moieties. Xenobiotica 53, 288\u2013308 (2023).","journal-title":"Xenobiotica"},{"key":"1535_CR135","doi-asserted-by":"crossref","unstructured":"Kots, M., Singh, D., Maison-Blanche, P., Piccinno, A. & Guasconi, A. CHF-6366: a novel dual potent bronchodilator with antimuscarinic and \u03b22 agonist activity \u2014 results from the first-in-human healthy male volunteers trial. In American Thoracic Society International Conference Meetings Abstracts Abstr. A2253 (Oxford Univ. Press, 2021).","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A2253"},{"key":"1535_CR136","first-page":"3972315","volume":"67","author":"L Carzaniga","year":"2024","unstructured":"Carzaniga, L. et al. Lung-targeted M3 antagonist\u2013\u03b22 agonist (MABA) dual pharmacology molecules for the inhaled treatment of respiratory diseases: discovery strategy and pharmacological validation of the clinical candidate CHF-6366 and its back-up compound CHF-6550. ACS Natl Meet. Abstr. 67, 3972315 (2024).","journal-title":"ACS Natl Meet. Abstr."},{"key":"1535_CR137","doi-asserted-by":"publisher","first-page":"9816","DOI":"10.1021\/acs.jmedchem.4c00298","volume":"67","author":"L Carzaniga","year":"2024","unstructured":"Carzaniga, L. et al. Discovery, multiparametric optimization, and solid-state driven identification of CHF-6550, a novel soft dual pharmacology muscarinic antagonist and \u03b22 agonist (MABA) for the inhaled treatment of respiratory diseases. J. Med. Chem. 67, 9816\u20139841 (2024).","journal-title":"J. Med. Chem."},{"key":"1535_CR138","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1124\/dmd.121.000632","volume":"50","author":"AA Holmberg","year":"2022","unstructured":"Holmberg, A. A. et al. Characterization of clinical absorption, distribution, metabolism, and excretion and pharmacokinetics of velsecorat using an intravenous microtracer combined with an inhaled dose in healthy subjects. Drug Metab. Dispos. 50, 150\u2013157 (2022).","journal-title":"Drug Metab. Dispos."},{"key":"1535_CR139","doi-asserted-by":"crossref","unstructured":"Chupp, G. L. et al. Results of a phase 2b dose finding study of velsecorat, an inhaled non-steroidal, selective Glucocorticoid Receptor Modulator in Asthma (GRANIT). In American Thoracic Society International Conference Meetings Abstracts A1202 (Oxford Univ. Press. 2021).","DOI":"10.1164\/ajrccm-conference.2021.203.1_MeetingAbstracts.A1202"},{"key":"1535_CR140","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12931-019-1000-7","volume":"20","author":"MN Brown","year":"2019","unstructured":"Brown, M. N. et al. Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double-blind, placebo-controlled crossover trial. Respir. Res. 20, 37 (2019).","journal-title":"Respir. Res."},{"key":"1535_CR141","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/14656566.2022.2083955","volume":"23","author":"M Cazzola","year":"2022","unstructured":"Cazzola, M., Rogliani, P., Naviglio, S., Calzetta, L. & Matera, M. G. An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. Expert Opin. Pharmacother. 23, 1205\u20131216 (2022).","journal-title":"Expert Opin. Pharmacother."},{"key":"1535_CR142","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13896","volume":"17","author":"Q Jiang","year":"2024","unstructured":"Jiang, Q. et al. Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu-like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the Toll-like receptor 7 agonist ruzotolimod. Clin. Transl. Sci. 17, e13896 (2024).","journal-title":"Clin. Transl. Sci."},{"key":"1535_CR143","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1021\/jm100070n","volume":"53","author":"A Kurimoto","year":"2010","unstructured":"Kurimoto, A. et al. Synthesis and biological evaluation of 8-oxoadenine derivatives as Toll-like receptor 7 agonists introducing the antedrug concept. J. Med. Chem. 53, 2964\u20132972 (2010).","journal-title":"J. Med. Chem."},{"key":"1535_CR144","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.taap.2017.11.002","volume":"338","author":"J Bell","year":"2018","unstructured":"Bell, J. et al. Temporal cytokine and lymphoid responses to an inhaled TLR7 antedrug agonist in the cynomolgus monkey demonstrate potential safety and tolerability of this approach. Toxicol. Appl. Pharmacol. 338, 9\u201319 (2018).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1535_CR145","first-page":"e000xx","volume":"3","author":"S Delaney","year":"2016","unstructured":"Delaney, S. et al. Tolerability in man following inhalation dosing of the selective TLR7 agonist AZD8848. BMJ Open Respir. Res. 3, e000xx (2016).","journal-title":"BMJ Open Respir. Res."},{"key":"1535_CR146","doi-asserted-by":"crossref","unstructured":"Greiff, L. et al. Efficacy and tolerability of the Toll-like receptor 7 agonist AZD8848 in patients with seasonal allergic rhinitis. In American Thoracic Society International Conference Meetings Abstracts Abstr. A4189 (Oxford Univ. Press, 2012).","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A4189"},{"key":"1535_CR147","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1465-9921-13-53","volume":"13","author":"L Greiff","year":"2012","unstructured":"Greiff, L. et al. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir. Res. 13, 53 (2012).","journal-title":"Respir. Res."},{"key":"1535_CR148","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06181370 (2023)."},{"key":"1535_CR149","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/0192623311416259","volume":"39","author":"MJ Anderton","year":"2011","unstructured":"Anderton, M. J. et al. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicol. Pathol. 39, 916\u2013924 (2011).","journal-title":"Toxicol. Pathol."},{"key":"1535_CR150","unstructured":"Bosser Artal, R., Pampin Casal, B. & Palomino Laria, J. C. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i\/alk5. Patent WO2022\/069509 (2021)."},{"key":"1535_CR151","unstructured":"Loo, M. et al. Substituted pyrimidines and method of use. Patent WO 2021203131 (2021)."},{"key":"1535_CR152","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1016\/j.bmcl.2014.07.016","volume":"24","author":"S Boland","year":"2014","unstructured":"Boland, S. et al. Novel roflumilast analogues as soft PDE4 inhibitors. Bioorg. Med. Chem. Lett. 24, 4594\u20134597 (2014).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1535_CR153","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1039\/D5MD00173K","volume":"16","author":"M Hemmerling","year":"2025","unstructured":"Hemmerling, M. et al. Topical BET PROTACs for locally restricted protein degradation in the lung. RSC Med. Chem. 16, 4183\u20134193 (2025).This study extends soft-drug design to targeted protein degradation by incorporating a metabolically labile element into an inhaled BET PROTAC to promote locally restricted activity.","journal-title":"RSC Med. Chem."},{"key":"1535_CR154","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.2174\/0929867324666170810154414","volume":"24","author":"H Cao","year":"2017","unstructured":"Cao, H., Wang, K., Ye, Y. L. & Shen, J. H. Orally administered small-molecule drugs with intestine-targeted profiles: recent development and prospects. Curr. Med. Chem. 24, 3921\u20133937 (2017).","journal-title":"Curr. Med. Chem."},{"key":"1535_CR155","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1021\/acsmedchemlett.3c00001","volume":"14","author":"R Dorel","year":"2023","unstructured":"Dorel, R., Wong, A. R. & Crawford, J. J. Trust your gut: strategies and tactics for intestinally restricted drugs. ACS Med. Chem. Lett. 14, 233\u2013243 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"1535_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.pmch.2015.10.001","volume":"55","author":"MCT Fyfe","year":"2016","unstructured":"Fyfe, M. C. T. Non-systemic intestine-targeted drugs. Prog. Med. Chem. 55, 1\u201344 (2016).","journal-title":"Prog. Med. Chem."},{"key":"1535_CR157","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41564-024-01810-x","volume":"9","author":"UH Manjunatha","year":"2024","unstructured":"Manjunatha, U. H. et al. Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted parasiticidal agent. Nat. Microbiol. 9, 2817\u20132835 (2024).This study provides a compelling example of a gut-restricted soft drug achieving potent intestinal efficacy together with rapid systemic elimination and clinical translation.","journal-title":"Nat. Microbiol."},{"key":"1535_CR158","unstructured":"Bootsma, A. N. Heterocyclic sik inhibitors. Patent WO2024062360 (2024)."},{"key":"1535_CR159","unstructured":"Ebner, D. et al. Development of colon-targeted pan-SIK inhibitor PF-07899895 for the treatment of IBD. In ACS Fall 2025 First Time Disclosure (ACS, 2025)."},{"key":"1535_CR160","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1016\/j.bmc.2014.05.045","volume":"22","author":"K Hasumi","year":"2014","unstructured":"Hasumi, K. et al. Design and synthesis of 5-[(2- chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept. Bioorg. Med. Chem. 22, 4162\u20134176 (2014).","journal-title":"Bioorg. Med. Chem."},{"key":"1535_CR161","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1124\/dmd.114.060046","volume":"43","author":"K Shirota","year":"2015","unstructured":"Shirota, K. et al. Analysis of the disposition of a novel p38 MAPK inhibitor, AKP-001, and its metabolites in rats with a simple physiologically based pharmacokinetic model. Drug Metab. Dispos. 43, 217\u2013226 (2015).","journal-title":"Drug Metab. Dispos."},{"key":"1535_CR162","doi-asserted-by":"publisher","first-page":"11570","DOI":"10.1021\/acs.jmedchem.1c00890","volume":"64","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. Gut-restricted selective cyclooxygenase-2 (COX-2) inhibitors for chemoprevention of colorectal cancer. J. Med. Chem. 64, 11570\u201311596 (2021).","journal-title":"J. Med. Chem."},{"key":"1535_CR163","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fphys.2016.00646","volume":"7","author":"C Guo","year":"2016","unstructured":"Guo, C., Chen, W. D. & Wang, Y. D. TGR5, not only a metabolic regulator. Front. Physiol. 7, 646 (2016).","journal-title":"Front. Physiol."},{"key":"1535_CR164","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.3390\/nu12092598","volume":"12","author":"MM Holter","year":"2020","unstructured":"Holter, M. M., Chirikjian, M. K., Govani, V. N. & Cummings, B. P. TGR5 signaling in hepatic metabolic health. Nutrients 12, 2598 (2020).","journal-title":"Nutrients"},{"key":"1535_CR165","doi-asserted-by":"publisher","first-page":"112619","DOI":"10.1016\/j.ejmech.2020.112619","volume":"203","author":"F Han","year":"2020","unstructured":"Han, F. et al. Design of G-protein-coupled bile acid receptor 1 (GPBAR1, TGR5) soft drugs with reduced gallbladder-filling effects. Eur. J. Med. Chem. 203, 112619 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"1535_CR166","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bmc.2014.11.018","volume":"23","author":"T Matsufuji","year":"2015","unstructured":"Matsufuji, T. et al. Synthesis and biological evaluation of novel chiral diazepine derivatives as bombesin receptor subtype-3 agonists incorporating an antedrug approach. Bioorg. Med. Chem. 23, 89\u2013104 (2015).","journal-title":"Bioorg. Med. Chem."},{"key":"1535_CR167","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","volume":"2","author":"A Patel","year":"2013","unstructured":"Patel, A., Cholkar, K., Agrahari, V. & Mitra, A. K. Ocular drug delivery systems: an overview. World J. Pharmacol. 2, 47\u201364 (2013).","journal-title":"World J. Pharmacol."},{"key":"1535_CR168","doi-asserted-by":"publisher","first-page":"E820","DOI":"10.1208\/aapsj070479","volume":"7","author":"N Bodor","year":"2005","unstructured":"Bodor, N. & Buchwald, P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 7, E820\u2013E833 (2005).This authorative review established the eye as a metabolically active compartment and defined how ocular metabolism can be exploited in soft drug design.","journal-title":"AAPS J."},{"key":"1535_CR169","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/OPTH.S118409","volume":"10","author":"A Farkouh","year":"2016","unstructured":"Farkouh, A., Frigo, P. & Czejka, M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin. Ophthalmol. 10, 2433\u20132441 (2016).","journal-title":"Clin. Ophthalmol."},{"key":"1535_CR170","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2174\/1874364101711010305","volume":"11","author":"A Vaajanen","year":"2017","unstructured":"Vaajanen, A. & Vapaatalo, H. A single drop in the eye \u2014 effects on the whole body? Open Ophthalmol. J. 11, 305\u2013314 (2017).","journal-title":"Open Ophthalmol. J."},{"key":"1535_CR171","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40123-014-0021-z","volume":"3","author":"L Schopf","year":"2014","unstructured":"Schopf, L., Enlow, E. & Popov, A. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation. Ophthalmol. Ther. 3, 63\u201372 (2014).","journal-title":"Ophthalmol. Ther."},{"key":"1535_CR172","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","volume":"57","author":"EM Del Amo","year":"2017","unstructured":"Del Amo, E. M. et al. Pharmacokinetic aspects of retinal drug delivery. Prog. Retin. Eye Res. 57, 134\u2013185 (2017).","journal-title":"Prog. Retin. Eye Res."},{"key":"1535_CR173","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/12030373","volume":"12","author":"AM Al-Ghananeem","year":"2007","unstructured":"Al-Ghananeem, A. M. & Crooks, P. A. Molecules phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules 12, 373\u2013388 (2007).","journal-title":"Molecules"},{"key":"1535_CR174","doi-asserted-by":"publisher","first-page":"114637","DOI":"10.1016\/j.ejpb.2025.114637","volume":"208","author":"RG Arribada","year":"2025","unstructured":"Arribada, R. G., Rodrigues-Braz, D., Silva-Cunha, A. & Behar-Cohen, F. Excipients in drug delivery systems: A comprehensive review of approved inactive ingredients for human ophthalmic formulations. Eur. J.Pharm. Biopharm. 208, 114637 (2025).","journal-title":"Eur. J.Pharm. Biopharm."},{"key":"1535_CR175","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/0113894501286195231220094646","volume":"25","author":"J Wu","year":"2024","unstructured":"Wu, J., Wei, J., Chen, H., Dang, Y. & Lei, F. Rho kinase (ROCK) inhibitors for the treatment of glaucoma. Curr. Drug Targets 25, 94\u2013107 (2024).","journal-title":"Curr. Drug Targets"},{"key":"1535_CR176","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1016\/j.bmcl.2013.09.040","volume":"23","author":"S Boland","year":"2013","unstructured":"Boland, S. et al. 3-[2-(Aminomethyl)-5-[(pyridin-4-yl)carbamoyl]phenyl] benzoates as soft ROCK inhibitors. Bioorg. Med. Chem. Lett. 23, 6442\u20136446 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1535_CR177","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1167\/iovs.13-13157","volume":"55","author":"S Van de Velde","year":"2014","unstructured":"Van de Velde, S. et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest. Ophthalmol. Vis. Sci. 55, 1006\u20131016 (2014).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1535_CR178","first-page":"565","volume":"55","author":"J Hall","year":"2014","unstructured":"Hall, J. et al. Initial clinical evaluation of safety, tolerability and pharmacodynamics of the locally-acting ROCK inhibitor AMA0076. Invest. Ophthamol. Vis. Sci. 55, 565 (2014).","journal-title":"Invest. Ophthamol. Vis. Sci."},{"key":"1535_CR179","doi-asserted-by":"publisher","first-page":"14690","DOI":"10.3390\/ijms232314690","volume":"23","author":"KW Kim","year":"2022","unstructured":"Kim, K. W., Shin, Y. J. & Lee, S. C. Novel ROCK inhibitors, sovesudil and PHP-0961, enhance proliferation, adhesion and migration of corneal endothelial cells. Int. J. Mol. Sci. 23, 14690 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1535_CR180","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1111\/aos.14949","volume":"100","author":"A Ha","year":"2022","unstructured":"Ha, A. et al. Sovesudil (locally acting Rho kinase inhibitor) for the treatment of normal-tension glaucoma: a randomized phase II study. Acta Ophthalmol. 100, e470\u2013e477 (2022).","journal-title":"Acta Ophthalmol."},{"key":"1535_CR181","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1021\/acs.jmedchem.5b00308","volume":"58","author":"S Boland","year":"2015","unstructured":"Boland, S. et al. Design, synthesis, and biological evaluation of novel, highly active soft ROCK inhibitors. J. Med. Chem. 58, 4309\u20134324 (2015).This study shows how potency, ocular stability, and rapid plasma hydrolysis can be combined in the rational design of locally acting soft ROCK inhibitors.","journal-title":"J. Med. Chem."},{"key":"1535_CR182","unstructured":"Leysen, D., Defert, O. & Boland, S. Novel soft rock inhibitors. Patent WO2013030216 (2013)."},{"key":"1535_CR183","unstructured":"Boland, S., Bourin, A., Defert, O. & Leysen, D. Pyridine derivatives as soft rock inhibitors. Patent WO2014118133 (2014)."},{"key":"1535_CR184","first-page":"108","volume":"57","author":"A Buchwald","year":"2002","unstructured":"Buchwald, A. et al. Soft cannabinoid analogues as potential anti-glaucoma agents. Pharmazie 57, 108\u2013114 (2002).","journal-title":"Pharmazie"},{"key":"1535_CR185","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/ph11020050","volume":"11","author":"S Miller","year":"2018","unstructured":"Miller, S. et al. Controlled-deactivation CB1 receptor ligands as a novel strategy to lower intraocular pressure. Pharmaceuticals 11, 50 (2018).","journal-title":"Pharmaceuticals"},{"key":"1535_CR186","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1021\/acsmedchemlett.4c00290","volume":"15","author":"A Rich","year":"2024","unstructured":"Rich, A. et al. Machine learning ADME models in practice: four guidelines from a successful lead optimization case study. ACS Med. Chem. Lett. 15, 1169\u20131173 (2024).","journal-title":"ACS Med. Chem. Lett."},{"key":"1535_CR187","doi-asserted-by":"publisher","first-page":"103728","DOI":"10.1016\/j.drudis.2023.103728","volume":"28","author":"J Zhai","year":"2023","unstructured":"Zhai, J., Man, V. H., Ji, B., Cai, L. & Wang, J. Comparison and summary of in silico prediction tools for CYP450-mediated drug metabolism. Drug Discov. Today 28, 103728 (2023).","journal-title":"Drug Discov. Today"},{"key":"1535_CR188","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1517\/17460441.2.7.923","volume":"2","author":"P Buchwald","year":"2007","unstructured":"Buchwald, P. Computer-aided retrometabolic drug design: soft drugs. Expert Opin. Drug Discov. 2, 923\u2013933 (2007).","journal-title":"Expert Opin. Drug Discov."},{"key":"1535_CR189","doi-asserted-by":"publisher","first-page":"23676","DOI":"10.1021\/acs.jmedchem.5c01911","volume":"68","author":"L Gioiello","year":"2025","unstructured":"Gioiello, L., Di Martino, R. M. C. & Pirali, T. Expanding the scope of PROTACs: opportunities and challenges in topical delivery. J. Med. Chem. 68, 23676\u201323689 (2025).","journal-title":"J. Med. Chem."},{"key":"1535_CR190","doi-asserted-by":"publisher","first-page":"15841","DOI":"10.1021\/jacs.6b10589","volume":"138","author":"BW Zaro","year":"2016","unstructured":"Zaro, B. W., Whitby, L. R., Lum, K. M. & Cravatt, B. F. Metabolically labile fumarate esters impart kinetic selectivity to irreversible inhibitors. J. Am. Chem. Soc. 138, 15841\u201315844 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"1535_CR191","doi-asserted-by":"publisher","first-page":"9495","DOI":"10.1021\/acs.jmedchem.4c00598","volume":"67","author":"CC Marvin","year":"2024","unstructured":"Marvin, C. C. et al. Anti-TNF thioester glucocorticoid antibody\u2013drug conjugate fully inhibits inflammation with minimal effect on systemic corticosterone levels in a mouse arthritis model. J. Med. Chem. 67, 9495\u20139515 (2024).This study expands soft drug design beyond conventional small molecules by using a metabolically controlled glucocorticoid ADC payload to preserve efficacy while minimizing systemic endrocrine effects.","journal-title":"J. Med. Chem."},{"key":"1535_CR192","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.chom.2026.06.001","volume":"34","author":"F Guo","year":"2026","unstructured":"Guo, F., Bay, Y. & Lei, X. Gut microbiota alters drug metabolism and therapeutic outcomes. Cell Host Microbe 34, 1262\u20131272 (2026).","journal-title":"Cell Host Microbe"},{"key":"1535_CR193","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/s41579-025-01211-9","volume":"23","author":"J Oh","year":"2025","unstructured":"Oh, J. & Voigt, A. Y. The human skin microbiome: from metagenomes to therapeutics. Nat. Rev. Microbiol. 23, 771\u2013787 (2025).","journal-title":"Nat. Rev. Microbiol."},{"key":"1535_CR194","doi-asserted-by":"publisher","first-page":"6S","DOI":"10.1093\/bja\/58.suppl_1.6S","volume":"58","author":"S Ward","year":"1986","unstructured":"Ward, S. & Weatherley, B. C. Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Br. J. Anaesth. 58, 6S\u201310S (1986).","journal-title":"Br. J. Anaesth."},{"key":"1535_CR195","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1097\/ALN.0b013e31819fade3","volume":"110","author":"M Jonsson Fagerlund","year":"2009","unstructured":"Jonsson Fagerlund, M., Dabrowski, M. & Eriksson, L. I. Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology 110, 1244\u20131252 (2009).","journal-title":"Anesthesiology"},{"key":"1535_CR196","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/bja\/76.5.624","volume":"76","author":"AM De Wolf","year":"1996","unstructured":"De Wolf, A. M. et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br. J. Anaesth. 76, 624\u2013628 (1996).","journal-title":"Br. J. Anaesth."},{"key":"1535_CR197","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2165\/00003495-199753050-00012","volume":"53","author":"HM Bryson","year":"1997","unstructured":"Bryson, H. M. & Faulds, D. Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Drugs 53, 848\u2013866 (1997).","journal-title":"Drugs"},{"key":"1535_CR198","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00228-012-1260-3","volume":"68","author":"WB Smith","year":"2012","unstructured":"Smith, W. B. et al. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension. Eur. J. Clin. Pharmacol. 68, 1385\u20131394 (2012).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"1535_CR199","doi-asserted-by":"publisher","first-page":"A3","DOI":"10.1002\/j.1552-4604.1986.tb02985.x","volume":"26","author":"RD Reynolds","year":"1986","unstructured":"Reynolds, R. D., Gorczynski, R. J. & Quon, C. Y. Pharmacology and pharmacokinetics of esmolol. J. Clin. Pharmacol. 26, A3\u2013A14 (1986).","journal-title":"J. Clin. Pharmacol."},{"key":"1535_CR200","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3390\/pharmaceutics16040517","volume":"16","author":"M Floria","year":"2024","unstructured":"Floria, M. et al. An overview of the pharmacokinetics and pharmacodynamics of landiolol (an ultra-short acting \u03b21 selective antagonist) in atrial fibrillation. Pharmaceutics 16, 517 (2024).","journal-title":"Pharmaceutics"},{"key":"1535_CR201","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1093\/eurheartj\/sux037","volume":"20","author":"H Domanovits","year":"2018","unstructured":"Domanovits, H., Wolzt, M. & Stix, G. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. Eur. Heart J. Suppl. 20, A1\u2013A3 (2018).","journal-title":"Eur. Heart J. Suppl."},{"key":"1535_CR202","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1034\/j.1399-6576.2002.460609.x","volume":"46","author":"D \u00d8stergaard","year":"2002","unstructured":"\u00d8stergaard, D., Viby-Mogensen, J., Pedersen, N. A., Holm, H. & Skovgaard, L. T. Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients. Acta Anaesthesiol. Scand. 46, 684\u2013691 (2002).","journal-title":"Acta Anaesthesiol. Scand."},{"key":"1535_CR203","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0952-8180(92)90034-X","volume":"4","author":"SJ Basta","year":"1992","unstructured":"Basta, S. J. Clinical pharmacology of mivacurium chloride: a review. J. Clin. Anesth. 4, 153\u2013163 (1992).","journal-title":"J. Clin. Anesth."},{"key":"1535_CR204","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0952-8180(96)00179-1","volume":"8","author":"LG Michelsen","year":"1996","unstructured":"Michelsen, L. G. & Hug, C. C. J. The pharmacokinetics of remifentanil. J. Clin. Anesth. 8, 679\u2013682 (1996).","journal-title":"J. Clin. Anesth."},{"key":"1535_CR205","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/00003495-199652030-00009","volume":"52","author":"SS Patel","year":"1996","unstructured":"Patel, S. S. & Spencer, C. M. Remifentanil. Drugs 52, 417\u2013427 (1996).","journal-title":"Drugs"},{"key":"1535_CR206","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1097\/00000542-199311000-00005","volume":"79","author":"CL Westmoreland","year":"1993","unstructured":"Westmoreland, C. L., Hoke, J. F., Sebel, P. S., Hug, C. C. & Muir, K. T. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 79, 893\u2013903 (1993).","journal-title":"Anesthesiology"},{"key":"1535_CR207","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17085\/apm.21115","volume":"17","author":"KM Kim","year":"2022","unstructured":"Kim, K. M. Remimazolam: pharmacological characteristics and clinical applications in anesthesiology. Anesth. Pain Med. 17, 1\u201311 (2022).","journal-title":"Anesth. Pain Med."},{"key":"1535_CR208","doi-asserted-by":"publisher","first-page":"24514","DOI":"10.52965\/001c.24514","volume":"9","author":"N Noor","year":"2021","unstructured":"Noor, N. et al. A comprehensive review of remimazolam for sedation. Health Psychol. Res. 9, 24514 (2021).","journal-title":"Health Psychol. Res."},{"key":"1535_CR209","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4137\/CCRPM.S8140","volume":"7","author":"DJ Reid","year":"2013","unstructured":"Reid, D. J. & Pham, N. T. Emerging therapeutic options for the management of COPD. Clin. Med. Insights Circ. Respir. Pulm. Med. 7, 7\u201315 (2013).","journal-title":"Clin. Med. Insights Circ. Respir. Pulm. Med."},{"key":"1535_CR210","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/pde.12872","volume":"33","author":"LT Zane","year":"2016","unstructured":"Zane, L. T. et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study. Pediatr. Dermatol. 33, 380\u2013387 (2016).","journal-title":"Pediatr. Dermatol."},{"key":"1535_CR211","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0954-6111(08)80004-2","volume":"84","author":"SM Harding","year":"1990","unstructured":"Harding, S. M. The human pharmacology of fluticasone propionate. Respir. Med. 84, 25\u201329 (1990).","journal-title":"Respir. Med."},{"key":"1535_CR212","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0954-6111(08)80003-0","volume":"84","author":"GH Phillipps","year":"1990","unstructured":"Phillipps, G. H. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir. Med. 84, 19\u201323 (1990).","journal-title":"Respir. Med."},{"key":"1535_CR213","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1046\/j.1365-2125.1996.36110.x","volume":"41","author":"AE Mackie","year":"1996","unstructured":"Mackie, A. E., Ventresca, G. P., Fuller, R. W. & Bye, A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br. J. Clin. Pharmacol. 41, 539\u2013542 (1996).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1535_CR214","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40262-012-0021-x","volume":"52","author":"A Allen","year":"2013","unstructured":"Allen, A., Bareille, P. J. & Rousell, V. M. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin. Pharmacokinet. 52, 37\u201342 (2013).","journal-title":"Clin. Pharmacokinet."},{"key":"1535_CR215","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0022-4731(75)90130-2","volume":"6","author":"H Laurent","year":"1975","unstructured":"Laurent, H., Gerhards, E. & Wiechert, R. New biologically active pregnan-21-oic acid esters. J. Steroid Biochem. 6, 185\u2013192 (1975).","journal-title":"J. Steroid Biochem."},{"key":"1535_CR216","first-page":"2226","volume":"27","author":"U Herz-H\u00fcbner","year":"1977","unstructured":"Herz-H\u00fcbner, U. & T\u00e4uber, U. Metabolisierung von fluocortin-butylester in der haut von meerschweinchen und mensch. Arzneimittelforschung 27, 2226\u20132229 (1977).","journal-title":"Arzneimittelforschung"},{"key":"1535_CR217","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0091-6749(85)80024-5","volume":"75","author":"TF Hartley","year":"1985","unstructured":"Hartley, T. F. et al. Efficacy and tolerance of fluocortin butyl administered twice daily in adult patients with perennial rhinitis. J. Allergy Clin. Immunol. 75, 501\u2013507 (1985).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1535_CR218","first-page":"2230","volume":"27","author":"W M\u00fctzel","year":"1977","unstructured":"M\u00fctzel, W. Pharmakokinetik und biotransformation von fluocortin-butylester beim menschen. Arzneimittelforschung 27, 2230\u20132233 (1977).","journal-title":"Arzneimittelforschung"},{"key":"1535_CR219","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10792-012-9589-2","volume":"32","author":"M Amon","year":"2012","unstructured":"Amon, M. & Busin, M. Loteprednol etabonate ophthalmic suspension 0.5%: efficacy and safety for postoperative anti-inflammatory use. Int. Ophthalmol. 32, 507\u2013517 (2012).","journal-title":"Int. Ophthalmol."},{"key":"1535_CR220","doi-asserted-by":"publisher","unstructured":"Comstock, T. L. & DeCory, H. H. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int. J. Inflamm. https:\/\/doi.org\/10.1155\/2012\/789623 (2012).","DOI":"10.1155\/2012\/789623"},{"key":"1535_CR221","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1111\/j.1468-3083.1994.tb01060.x","volume":"3","author":"U T\u00e4uber","year":"1994","unstructured":"T\u00e4uber, U. Pharmacokinetics and \u2018bioactivation\u2019 of MPA. J. Eur. Acad. Dermatol. Venereol. 3, S23 (1994).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1535_CR222","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1368-5031.2005.00754.x","volume":"60","author":"T Ruzicka","year":"2006","unstructured":"Ruzicka, T. Methylprednisolone aceponate in eczema and other inflammatory skin disorders \u2014 a clinical update. Int. J. Clin. Pract. 60, 85\u201392 (2006).","journal-title":"Int. J. Clin. Pract."},{"key":"1535_CR223","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF03259059","volume":"3","author":"M Haria","year":"1995","unstructured":"Haria, M. & Balfour, J. A. Methylprednisolone aceponate. Clin. Immunother. 3, 241 (1995).","journal-title":"Clin. Immunother."},{"key":"1535_CR224","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000029806","volume":"11","author":"C G\u00fcnther","year":"1998","unstructured":"G\u00fcnther, C., Kecskes, A., Staks, T. & T\u00e4uber, U. Percutaneous absorption of methylprednisolone aceponate following topical application of Advantan lotion on intact, inflamed and stripped skin of male volunteers. Skin Pharmacol. Appl. Skin Physiol. 11, 35\u201342 (1998).","journal-title":"Skin Pharmacol. Appl. Skin Physiol."},{"key":"1535_CR225","first-page":"179","volume":"6","author":"J Barth","year":"1993","unstructured":"Barth, J. et al. Studies on the pharmacokinetics and metabolism of prednicarbate after cutaneous and oral administration. Skin Pharmacol. 6, 179\u2013186 (1993).","journal-title":"Skin Pharmacol."},{"key":"1535_CR226","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10227-004-0120-x","volume":"8","author":"AK Gupta","year":"2004","unstructured":"Gupta, A. K. & Chow, M. Prednicarbate (Dermatop): profile of a corticosteroid. J. Cutan. Med. Surg. 8, 244\u2013247 (2004).","journal-title":"J. Cutan. Med. Surg."},{"key":"1535_CR227","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.pupt.2017.10.003","volume":"48","author":"D Quinn","year":"2018","unstructured":"Quinn, D. et al. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): results of two randomized, double-blind, phase 2 studies. Pulm. Pharmacol. Ther. 48, 71\u201379 (2018).","journal-title":"Pulm. Pharmacol. Ther."},{"key":"1535_CR228","unstructured":"Multi-Discipline Review and Evaluation: NDA 217347, Sofdra (Sofpironium) topical gel, 12.45%. Center for Drug Evaluation and Research (US Food and Drug Administration, 2024)."},{"key":"1535_CR229","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/17476348.2016.1184976","volume":"10","author":"M Malerba","year":"2016","unstructured":"Malerba, M., Radaeli, A., Montuschi, P. & Morjaria, J. B. Vilanterol trifenatate for the treatment of COPD. Expert Rev. Respir. Med. 10, 719\u2013731 (2016).","journal-title":"Expert Rev. Respir. Med."},{"key":"1535_CR230","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1476-5381.2011.01790.x","volume":"166","author":"M Biffen","year":"2012","unstructured":"Biffen, M. et al. Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity. Br. J. Pharmacol. 166, 573\u2013586 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"1535_CR231","doi-asserted-by":"publisher","unstructured":"Jain, M. et al. A first-in-human phase 1 clinical study in healthy volunteers to assess the safety, tolerability, and pharmacokinetics of EDI048, a novel promising agent to treat enteric cryptosporidiosis. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiag210 (2026).","DOI":"10.1093\/infdis\/jiag210"},{"key":"1535_CR232","unstructured":"Mannhold, R., Kubinyi, H. & Folkers, G. Prodrugs and Targeted Delivery: Towards Better ADME Properties (John Wiley & Sons, 2011)."},{"key":"1535_CR233","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4433-3","volume":"18","author":"B Arneth","year":"2018","unstructured":"Arneth, B. Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. BMC Cancer 18, 527 (2018).","journal-title":"BMC Cancer"},{"key":"1535_CR234","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11095-007-9429-7","volume":"25","author":"C Herkenne","year":"2008","unstructured":"Herkenne, C. et al. In vivo methods for the assessment of topical drug bioavailability. Pharm. Res. 25, 87\u2013103 (2008).","journal-title":"Pharm. Res."},{"key":"1535_CR235","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1517\/17425247.3.2.275","volume":"3","author":"D Ghate","year":"2006","unstructured":"Ghate, D. & Edelhauser, H. F. Ocular drug delivery. Expert Opin. Drug Deliv. 3, 275\u2013287 (2006).","journal-title":"Expert Opin. Drug Deliv."},{"key":"1535_CR236","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1389200219666180821094502","volume":"20","author":"L Di","year":"2019","unstructured":"Di, L. The impact of carboxylesterases in drug metabolism and pharmacokinetics. Curr. Drug Metab. 20, 91\u2013102 (2019).","journal-title":"Curr. Drug Metab."},{"key":"1535_CR237","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","volume":"8","author":"D Wang","year":"2018","unstructured":"Wang, D. et al. Human carboxylesterases: a comprehensive review. Acta Pharm. Sin. B 8, 699\u2013712 (2018).","journal-title":"Acta Pharm. Sin. B"},{"key":"1535_CR238","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2133\/dmpk.DMPK-12-RV-042","volume":"27","author":"T Fukami","year":"2012","unstructured":"Fukami, T. & Yokoi, T. The emerging role of human esterases. Drug Metab. Pharmacokinet. 27, 466\u2013477 (2012).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"1535_CR239","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/bdd.70003","volume":"46","author":"M Takahashi","year":"2025","unstructured":"Takahashi, M., Sakai, S., Takahashi, K. & Hosokawa, M. Species differences in carboxylesterases among humans, cynomolgus monkeys, and mice in the hydrolysis of atorvastatin derivatives. Biopharm. Drug Dispos. 46, 49\u201357 (2025).","journal-title":"Biopharm. Drug Dispos."},{"key":"1535_CR240","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1002\/jps.23258","volume":"101","author":"FG Bahar","year":"2012","unstructured":"Bahar, F. G., Ohura, K., Ogihara, T. & Imai, T. Species differences of esterase expression and hydrolase activity in plasma. J. Pharm. Sci. 101, 3979\u20133988 (2012).","journal-title":"J. Pharm. Sci."},{"key":"1535_CR241","doi-asserted-by":"publisher","first-page":"e41721","DOI":"10.1371\/journal.pone.0041721","volume":"7","author":"S Van Eijl","year":"2012","unstructured":"Van Eijl, S. et al. Elucidation of xenobiotic metabolism pathways in human skin and human skin models by proteomic profiling. PLoS ONE 7, e41721 (2012).","journal-title":"PLoS ONE"},{"key":"1535_CR242","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s11095-006-0273-y","volume":"23","author":"JJ Prusakiewicz","year":"2006","unstructured":"Prusakiewicz, J. J., Ackermann, C. & Voorman, R. Comparison of skin esterase activities from different species. Pharm. Res. 23, 1517\u20131524 (2006).","journal-title":"Pharm. Res."},{"key":"1535_CR243","doi-asserted-by":"publisher","first-page":"1700394","DOI":"10.1002\/pmic.201700394","volume":"18","author":"MT Ahmad","year":"2018","unstructured":"Ahmad, M. T., Zhang, P., Dufresne, C., Ferrucci, L. & Semba, R. D. The Human Eye Proteome Project: updates on an emerging proteome. Proteomics 18, 1700394 (2018).","journal-title":"Proteomics"},{"key":"1535_CR244","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1021\/acs.molpharmaceut.0c01154","volume":"18","author":"A Hammid","year":"2021","unstructured":"Hammid, A. et al. Carboxylesterase activities and protein expression in rabbit and pig ocular tissues. Mol. Pharm. 18, 1305\u20131316 (2021).","journal-title":"Mol. Pharm."},{"key":"1535_CR245","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0335361","volume":"20","author":"LM Schopfer","year":"2025","unstructured":"Schopfer, L. M., Tacal, O., Masson, P. & Lockridge, O. Kinetic analysis suggests that malathion at low environmental exposures is not toxic to humans. PLoS ONE 20, e0335361 (2025).","journal-title":"PLoS ONE"},{"key":"1535_CR246","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1124\/dmd.111.041475","volume":"40","author":"T Ishizuka","year":"2012","unstructured":"Ishizuka, T. et al. Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism. Drug Metab. Dispos. 40, 374\u2013380 (2012).","journal-title":"Drug Metab. Dispos."},{"key":"1535_CR247","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/17425255.2.6.875","volume":"2","author":"M Martignoni","year":"2006","unstructured":"Martignoni, M., Groothuis, G. M. M. & de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2, 875\u2013894 (2006).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"1535_CR248","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1074\/jbc.REV119.007741","volume":"295","author":"M Terao","year":"2020","unstructured":"Terao, M., Garattini, E., Rom\u00e3o, M. J. & Leimk\u00fchler, S. Evolution, expression, and substrate specificities of aldehyde oxidase enzymes in eukaryotes. J. Biol. Chem. 295, 5377\u20135389 (2020).","journal-title":"J. Biol. Chem."},{"key":"1535_CR249","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1021\/acs.jmedchem.1c01765","volume":"65","author":"CR Wellawa","year":"2022","unstructured":"Wellawa, C. R. et al. Investigation of janus kinase (JAK) inhibitors for lung delivery and the importance of aldehyde oxidase metabolism. J. Med. Chem. 65, 633\u2013664 (2022).","journal-title":"J. Med. Chem."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01535-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:01:43Z","timestamp":1790802103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01535-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":249,"alternative-id":["1535"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01535-y","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"25 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.P. is co-founder and shareholder of the spin-off company ChemiCare, Italy and is named as co-inventor on patent application WO2018206742, whose patent applicant is AntalGenics S.L., describing soft compounds with activity on TRPV1. L.C. and A.A. are employees of Chiesi Farmaceutici S.p.A. L.C. is named as co-inventor on patent applications WO201628456, WO2016193241, WO2017093208 and WO2018011090, whose patent applicant is Chiesi Farmaceutici S.p.A., describing compounds with muscarinic antagonist and \u03b2\n                      2\n                      agonist activity. J.R. declares no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}